Denmark’s Growth Upgrade and a DKK 11.2bn Buyback Propel Novo Nordisk’s Narrative

Copenhagen revises 2026 GDP forecast to 2.7% on booming pharma led by Novo Nordisk, despite US pricing headwinds and a 4-12% revenue decline forecast; stock up 10% in month but down 13% YTD.

Copenhagen has sharply revised its 2026 growth forecast to 2.7%, crediting the country’s booming pharmaceutical sector — with Novo Nordisk at its centre — as a primary catalyst. The upgrade underscores how deeply the drugmaker’s GLP-1 franchise now threads through the national economy, even as the company itself wrestles with pricing headwinds in its largest market. On the Copenhagen bourse, the stock has clawed back ground, gaining just over 10% in the past month to close at €38.74, though it remains roughly 13% lower year to date.

That share-price recovery has been helped along by a massive capital-return programme. Novo Nordisk has committed to buying back its own shares for up to DKK 11.2bn, with the purchases running until February 2027. The buyback is part of a larger tranche totalling DKK 15bn, signalling management’s conviction that the equity is undervalued against a rich pipeline of clinical milestones and regulatory decisions due in the second half.

The pipeline’s most closely watched near-term catalyst is in hepatology. At the EASL congress in Barcelona this week, Novo Nordisk is presenting new subgroup analyses from the phase?3 ESSENCE programme. The data show that semaglutide at 2.4 mg continues to deliver significant reductions in liver inflammation and fibrosis in patients with MASH, a progressive and often undiagnosed disease affecting an estimated 250 million people worldwide — nine out of ten cases remain hidden. The latest analysis also demonstrates a favourable safety profile across special populations, including menopausal women.

Obesity remains the core engine, however. Early in May, the STEP?UP study reported that high?dose Wegovy produced an average weight loss of nearly 28% among early responders, reinforcing the drug’s competitive edge even as rival therapies crowd the space. That data, together with the MASH news, helps explain why the company is willing to plough billions into its own stock.

Operationally, the picture is more nuanced. Reported revenue in the first quarter surged 32% on a currency?adjusted basis, but that figure was inflated by the reversal of a provision tied to a US pricing programme. Stripping out that one?off effect, sales actually contracted by 4%. Volume growth is being steadily eaten away by lower realised prices, particularly in the United States, where adjusted revenues slid 11%. International markets fared better, growing 6%, while the obesity segment as a whole advanced 22% on a currency?adjusted basis.

Management has responded by dialling down expectations. The full?year outlook now anticipates a decline in adjusted revenue of between 4% and 12%, with operating profit expected to shrink in a similar band — both ranges excluding the US pricing effect. The strong Danish macro backdrop does little to erase those company?specific pressures; the market’s focus will remain fixed on US pricing trends until the next major check?in.

That check?in arrives on 5 August, when Novo Nordisk publishes first?half results. The calendar is then packed: a Capital Markets Day on 21 September and, in the fourth quarter, the eagerly awaited US regulatory decision on the combination drug CagriSema. Until then, the tug?of?war between a supportive home economy, a hefty buyback, impressive clinical data, and persistent price erosion will keep investors on their toes.